ME

MEDINET Co., Ltd.

A CDMO providing one-stop solutions for regenerative medicine and cell therapy.

2370 | T

Overview

Corporate Details

ISIN(s):
JP3920990003
LEI:
Country:
Japan
Address:
品川区勝島一丁目5番21号

Description

MEDINET Co., Ltd. is a Contract Development and Manufacturing Organization (CDMO) specializing in regenerative medicine and cell therapy. The company provides comprehensive, one-stop solutions across the entire value chain, from pre-clinical research and process development to manufacturing and commercial launch. Its services encompass technology transfer, quality control, and quality assurance for regenerative medical products, investigational products, and specified cell products. MEDINET operates an advanced cell processing facility (CPF) designed to comply with international standards such as GCTP, leveraging extensive experience since 1999 to support clients in developing and manufacturing their cellular therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-17 08:10
訂正有価証券届出書(参照方式)
Japanese 116.1 KB
2025-12-17 07:33
確認書
Japanese 8.3 KB
2025-12-17 07:32
有価証券報告書-第30期(2024/10/01-2025/09/30)
Japanese 1.2 MB
2025-12-05 04:36
訂正有価証券届出書(参照方式)
Japanese 113.0 KB
2025-12-03 08:09
有価証券届出書(参照方式)
Japanese 173.2 KB
2025-05-14 08:33
確認書
Japanese 8.3 KB
2025-05-14 08:32
半期報告書-第30期(2024/10/01-2025/09/30)
Japanese 204.7 KB
2024-12-26 04:04
臨時報告書
Japanese 25.2 KB
2024-12-18 07:40
確認書
Japanese 8.3 KB
2024-12-18 07:38
内部統制報告書-第29期(2023/10/01-2024/09/30)
Japanese 21.6 KB
2024-12-18 07:35
有価証券報告書-第29期(2023/10/01-2024/09/30)
Japanese 1.3 MB
2024-05-14 08:02
確認書
Japanese 8.3 KB
2024-05-14 08:00
四半期報告書-第29期第2四半期(2024/01/01-2024/03/31)
Japanese 200.2 KB
2024-02-13 07:04
確認書
Japanese 8.3 KB
2024-02-13 07:01
四半期報告書-第29期第1四半期(2023/10/01-2023/12/31)
Japanese 152.4 KB

Automate Your Workflow. Get a real-time feed of all MEDINET Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MEDINET Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MEDINET Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.